Major adverse cardiovascular events in survivors of immune‐mediated thrombotic thrombocytopenic purpura-Reference-Cited by-同舟云学术

Major adverse cardiovascular events in survivors of immune‐mediated thrombotic thrombocytopenic purpura

Published:2021-09-15 Issue:12 Volume:96 Page:1587-1594
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Brodsky Max A.¹,Sukumar Senthil²,Selvakumar Sruthi³^ORCID,Yanek Lisa¹,Hussain Sarah⁴,Mazepa Marshall A.⁵,Braunstein Evan M.⁴,Moliterno Alison R.⁴,Kickler Thomas S.⁴,Brodsky Robert A.⁴,Cataland Spero R.²^ORCID,Chaturvedi Shruti⁴^ORCID

Affiliation:

1. Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Division of Hematology, Department of Medicine The Ohio State University College of Medicine Columbus Ohio USA

3. Nova Southeastern University School of Medicine Fort Lauderdale Florida USA

4. Division of Hematology, Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

5. Division of Hematology and Oncology University of Minnesota School of Medicine Minneapolis Minnesota USA

Funder

American Society of Hematology

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26341

Reference41 articles.

1. Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura

2. Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

3. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke

4. Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura

5. Improved Survival in Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome;Blood;2024-09-12

2. A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura;Journal of Blood Medicine;2024-08

3. ADAMTS13 in the New Era of TTP;International Journal of Molecular Sciences;2024-07-26

4. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons;Expert Review of Hematology;2024-02-20

5. Ambulatory Management of Thrombotic Thrombocytopenia Purpura: Will We Get There?;The Hematologist;2024